Organic Active Ingredients TRIZ Cases

Controlled anti-solvent crystallization creates a stable TETA.4HCl Form B that resists humidity and room-temperature degradation.

Milder bases and protected intermediates cut racemization and isomer impurities while improving N/O-alkylation selectivity and yield.

Bifunctional IRAK4 degraders recruit E3 ligases to drive ubiquitination and proteasomal removal, lowering IRAK4 with low toxicity.

Blocking IL-6 or IL-6R offers a targeted option for severe refractory asthma, reducing exacerbations and steroid dependence.

Modified mRNA plus microRNA mimics reprogram primary human fibroblasts into iPSCs without feeder cells or genomic integration.

Demethylating STING-deficient melanoma cells before STING agonist treatment boosts chemokine-driven T cell recruitment and TIL function.

By raising intracellular cAMP, PDE1 inhibition drives apoptosis and limits immune-cell recruitment, helping control colorectal cancer metastasis.

Autologous CD19 CAR-T cells paired with lymphodepleting chemotherapy improve refractory MCL and B-cell ALL treatment while managing CRS.

Controlled polymorphs and solvates make this benzofuran carboxamide more stable, non-hygroscopic, and suitable for consistent drug formulation.

Acellular amniotic fluid treats ischemic injury without invasive procedures, reducing infarct size, preserving cardiac function, and limiting fibrosis.

Alcohol-substituted imidazo[1,2-a]pyridines balance potent NMT inhibition with better cell permeability and metabolic stability for cancer therapy.

New ISR modulator compounds tune substituents to stabilize eIF2B, lower phosphorylated eIF2alpha, and improve solubility and selectivity.

Indoline derivatives act upstream to reduce oxidative stress and pro-inflammatory cytokine release while limiting adverse effects in chronic disorders.

A two-component PEG hydrogel sealant improves lung tissue compliance, adhesion, and visibility while setting quickly on a deflated lung.

A 5'-CP gapmer with modified wing regions preserves RPS25 silencing while reducing delayed central toxicity and supporting RNase-driven RNA degradation.

Alginate oligomers bind calcium to reduce dense clot formation, increase clot permeability, and improve anticoagulation response.

An oil-in-water emulsion uses amphoteric surfactant and alkoxylated cetyl alcohol to improve sodium cromoglicate skin delivery with low irritation.

Biotin functionalization boosts polymer uptake in pathogens and cancer cells while coacervate delivery reduces mammalian-cell toxicity.

A SIRPα-linked BRCA siRNA complex targets CD47-positive cancer cells to improve siRNA delivery and boost PARP inhibitor response in wild-type BRCA tumors.

Charge-neutralizing backbone moieties improve oligonucleotide uptake and membrane penetration while preserving stability for therapeutic use.

A crystalline fine-particle PRX-3140 potassium salt improves dissolution, stability, and absorption consistency for oral delivery.

Dry powder active agent placed on the adhesive contact surface improves transfer to the substrate while preserving bond strength and stability.

Using SP6 RNA polymerase, this case shows large-scale full-length mRNA production with low dsRNA contamination and no chromatography step.

Controlling liposomes to 90-110 nm with low polydispersity extends blood retention and sustains CD1d ligand levels for transplant therapy.

Local Wnt5a inhibition targets Schlemm's canal to lower intraocular pressure while avoiding the side effects and scarring of standard glaucoma treatments.

A stepwise acetylation-oxidation-demethylation route produces morin above 95% purity without kaempferol and avoids yellowwood extraction.

Reduced-frequency tralokinumab dosing maintains atopic dermatitis control while lowering injection burden, drug exposure, and steroid dependence.

A heat-treated ergothioneine derivative removes hydrogen peroxide and reduces related cytotoxicity across varied composition uses.

A ribose-based GalNAc monomer improves ASGPR-mediated liver delivery of oligonucleotides and strengthens AGT gene expression inhibition.

A piston-driven earplug chamber injects fluid into the ear canal while sealing against leakage and providing acoustic isolation.

Epigenetic inhibitors modulate EGFR amplification to reduce tumor heterogeneity and restore sensitivity to EGFR-targeted cancer drugs.

By regulating RNA m6A methylation, this indole compound targets hyperkeratosis at the cause and helps reduce stratum corneum thickness.

An LNP-delivered self-amplifying IL-12 replicon drives immunogenic cell death at the tumor site while extending immunity to distal tumors.

Local delivery of a formula (I) antibacterial targets Gram-positive diabetic foot infection, reducing biofilm and systemic side effects.

Controlled particle size, metal-free excipients, and wet granulation improve eltrombopag olamine tablet stability and dissolution.

Spirocyclic compounds lower EPO levels with strong chemical stability, offering a targeted option for renal cell carcinoma and polycythemia.

Sequence-specific zinc-finger arrays paired with a nuclease domain improve RHO locus cleavage specificity and editing efficiency for retinitis pigmentosa.

Roluperidone helps prevent schizophrenia relapse by stabilizing negative symptoms without dopamine-related Parkinsonism or sedation.

Mechanochemical mixing, extrusion, and continuous extraction improve nicotinoyl riboside yield, scale-up, and crystalline stability.

Berberine compositions target nicotinic acetylcholine receptors to curb dopamine release, reducing nicotine dependency with fewer side effects.

Biodegradable particles combine surface immune signals with encapsulated cytokines to expand Tregs and treat autoimmunity without broad immunosuppression.

Defined NK-1 antagonist crystal forms and solvates improve reproducibility, stability, solubility, and bioavailability for formulation.

Modified indole serotonin agonists aim to preserve rapid CNS therapeutic effects while reducing tolerance and adverse reactions.

Targeting Hedgehog-activated myofibroblasts with taladegib helps reduce fibrosis and improve lung function in progressive pulmonary fibrosis.

Combining anti-coagulants with B-Raf or MEK inhibitors helps curb OPN-associated melanoma growth and metastasis by modulating the tumor microenvironment.

A surfactant-based oral testosterone undecanoate formulation treats deficiency while maintaining blood pressure control and lowering cardiovascular risk.

Membrane-fusing liposome-coated porous silicon nanoparticles deliver genetic and other anionic cargo directly to cells while avoiding lysosomal degradation.

Metal salt forms of a tetrahydroisoquinoline AT2R antagonist improve water solubility and pharmacokinetics for neuropathic pain therapy.

Remodeled N297 glycan improves internalization of a CLDN6/CLDN9-targeting antibody-PBD conjugate, boosting tumor cell cytotoxicity.

Small-molecule NF-κB inhibitors selectively curb excessive inflammation while preserving needed immune response in autoimmune and cancer treatment.

Crystalline maleate salt forms improve water solubility and stability of a 3-cyanoquinoline cancer drug, boosting absorption over the free base.

Small molecules preferentially bind MTA-bound PRMT5 in MTAP-null tumors, improving efficacy while limiting toxicity in normal tissues.

Selective GABA A γ1 PAMs enhance inhibitory signaling for ASD-related symptoms while avoiding sedation linked to non-selective benzodiazepines.

A BMPR1B inhibitor in induction medium improves the efficiency and stability of directing pluripotent stem cells into neural lineage cells.

Targeting IL-17A with secukinumab offers faster rheumatoid arthritis symptom control in high-risk patients while avoiding broad DMARD toxicity.

Clinical use of vafidemstat targets core ASD symptoms and reduces aggression without the sedation or weight gain seen in current therapies.

Pre-capped oligonucleotide primers enable one-step synthesis of homogeneous Cap 0-2 RNAs with higher yield, lower cost, and reduced immunogenicity.

Liposomal mitoxantrone improves advanced breast cancer treatment by preserving efficacy while reducing cardiotoxicity and adverse effects.

Stable crystal and salt forms of a dual FLT3/IRAK4 inhibitor improve AML treatment by addressing resistance while maintaining strong physical stability.

Gut microbiota modulation with 2'-FL, 6'SL, and LNT raises kynurenic acid to reduce infant abdominal pain, crying, and sleep disruption.

Targeting ITPRIPL1 binding to CD3ε and NRP2 enables immune-response modulation and tumor suppression across multiple disease settings.

Specific salt, temperature, and loading time conditions raise EV payload association while reducing dissociation and improving delivery stability.

Formula I compounds improve plasma kallikrein inhibition specificity and therapeutic effect across hereditary angioedema and retinal edema disorders.

A natural flavonoid suppresses IL-17A and the IL-23/STAT3 pathway to reduce inflammation with fewer side effects.

A pressurized wound irrigation stream delivers chlorhexidine and octenidine together to cut irrigation time and lower microbial burden.

New quinazoline crystal forms improve blood-brain barrier penetration and ErbB2 selectivity for treating breast cancer brain metastases.

High-nicotine formulations use organic acids to limit evaporation and substrate spreading while keeping aerosol delivery stable and precise.

By recruiting LRRK2 to an E3 ubiquitin ligase, these PROTAC compounds overcome kinase inhibitor resistance through targeted degradation.

A steroid GABAA regulator crystal form enables once-daily oral dosing with antidepressant effects within 24 hours and sustained relief.

Combining NMN with mogroside V improves blood glucose control, protects islet cells, and inhibits fat accumulation at lower cost.

Stable solvent-free crystal forms reduce moisture uptake and improve processing of acetylcholinesterase inhibitors for neurodegenerative drugs.

Using Semaphorin 3B as a focused marker streamlines membranous nephropathy diagnosis and speeds immunosuppressive treatment decisions.

Novel nitrogen-containing bicyclic compounds inhibit IRAK-4 while reducing off-target effects and genetic toxicity in autoimmune therapy.

Novel tricyclic heterocycles improve KRas G12C inhibition while supporting oral delivery, better pharmacokinetics, and fewer adverse effects.

Modified KNG siRNA with a liver-targeting conjugate improves stability and specificity for septicemia treatment while limiting off-target effects.